• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Community-acquired Coinfection in Coronavirus Disease 2019: A Retrospective Observational Experience.社区获得性共感染在 2019 年冠状病毒病中的作用：一项回顾性观察研究。
Clin Infect Dis. 2021 Apr 26;72(8):1450-1452. doi: 10.1093/cid/ciaa902.
2
Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting.COVID-19 住院患者的细菌和真菌感染：英国二级保健机构中的回顾性队列研究。
Clin Microbiol Infect. 2020 Oct;26(10):1395-1399. doi: 10.1016/j.cmi.2020.06.025. Epub 2020 Jun 27.
3
A Retrospective Study of Coinfection of SARS-CoV-2 and Streptococcus pneumoniae in 11 Hospitalized Patients with Severe COVID-19 Pneumonia at a Single Center.一项单中心 11 例重症 COVID-19 肺炎住院患者中 SARS-CoV-2 与肺炎链球菌合并感染的回顾性研究。
Med Sci Monit. 2020 Nov 14;26:e928754. doi: 10.12659/MSM.928754.
4
Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Invasive Pneumococcal Disease and Risk of Pneumococcal Coinfection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Prospective National Cohort Study, England.新型冠状病毒病（COVID-19）大流行对侵袭性肺炎球菌病的影响以及与严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）发生肺炎球菌合并感染的风险：英格兰全国前瞻性队列研究。
Clin Infect Dis. 2021 Mar 1;72(5):e65-e75. doi: 10.1093/cid/ciaa1728.
5
Coinfection and Other Clinical Characteristics of COVID-19 in Children.儿童 COVID-19 的合并感染和其他临床特征。
Pediatrics. 2020 Jul;146(1). doi: 10.1542/peds.2020-0961. Epub 2020 May 6.
6
Risk factors and outcomes associated with community-onset and hospital-acquired coinfection in patients hospitalized for coronavirus disease 2019 (COVID-19): A multihospital cohort study.与 COVID-19 住院患者的社区获得性和医院获得性合并感染相关的风险因素和结局：一项多医院队列研究。
Infect Control Hosp Epidemiol. 2022 Sep;43(9):1184-1193. doi: 10.1017/ice.2021.341. Epub 2021 Jul 26.
7
Clinical Characteristics and Outcome of Hospitalized COVID-19 Patients in a MERS-CoV Endemic Area.在中东呼吸综合征冠状病毒流行地区住院的 COVID-19 患者的临床特征和转归。
J Epidemiol Glob Health. 2020 Sep;10(3):214-221. doi: 10.2991/jegh.k.200806.002.
8
Treatment of Community-Acquired Pneumonia During the Coronavirus Disease 2019 (COVID-19) Pandemic.COVID-19 大流行期间社区获得性肺炎的治疗。
Ann Intern Med. 2020 Aug 18;173(4):304-305. doi: 10.7326/M20-2189. Epub 2020 May 7.
9
Clinical characteristics of COVID-19 patients with hepatitis B virus infection - a retrospective study.COVID-19 患者合并乙型肝炎病毒感染的临床特征：一项回顾性研究。
Liver Int. 2021 Apr;41(4):720-730. doi: 10.1111/liv.14774. Epub 2021 Jan 10.
10
SARS-CoV-2-induced immunodysregulation and the need for higher clinical suspicion for co-infection and secondary infection in COVID-19 patients.SARS-CoV-2 诱导的免疫失调以及 COVID-19 患者需要更高的临床警惕以识别合并感染和继发感染。
J Microbiol Immunol Infect. 2021 Feb;54(1):105-108. doi: 10.1016/j.jmii.2020.08.016. Epub 2020 Sep 8.

引用本文的文献

1
A Rare Fatal Case of COVID-19 Co-Infection with Community-Acquired Methicillin-Resistant Staphylococcus Aureus in a Diabetic Patient.一名糖尿病患者新冠病毒病合并社区获得性耐甲氧西林金黄色葡萄球菌感染的罕见致死病例
Infect Drug Resist. 2025 Apr 17;18:1935-1939. doi: 10.2147/IDR.S512885. eCollection 2025.
2
Initial Empirical Antibiotic Treatment in Patients with COVID-19 is Associated with Excess Adverse Drug Reactions without Clinical Benefit.新冠病毒疾病患者的初始经验性抗生素治疗与额外的药物不良反应相关，且无临床获益。
Turk J Pharm Sci. 2025 Jan 10;21(6):489-498. doi: 10.4274/tjps.galenos.2023.44675.
3
Molecular pathogen profiling of COVID-19 coinfections.新冠病毒合并感染的分子病原体分析
BMC Infect Dis. 2024 Dec 19;24(1):1451. doi: 10.1186/s12879-024-10347-7.
4
Clinical characteristics of SARS-CoV-2 Omicron pneumonia in immunocompromised and immunocompetent patients: A retrospective cohort study.免疫功能低下和免疫功能正常患者的新型冠状病毒奥密克戎肺炎临床特征：一项回顾性队列研究
Heliyon. 2024 Oct 9;10(20):e39044. doi: 10.1016/j.heliyon.2024.e39044. eCollection 2024 Oct 30.
5
Secondary Bacterial Infections in Critically Ill COVID-19 Patients Admitted in the Intensive Care Unit of a Tertiary Hospital in Romania.罗马尼亚一家三级医院重症监护病房收治的危重症新冠肺炎患者的继发性细菌感染
J Clin Med. 2024 Oct 18;13(20):6201. doi: 10.3390/jcm13206201.
6
The long Pentraxin PTX3 serves as an early predictive biomarker of co-infections in COVID-19.长型 Pentraxin PTX3 可作为 COVID-19 合并感染的早期预测性生物标志物。
EBioMedicine. 2024 Jul;105:105213. doi: 10.1016/j.ebiom.2024.105213. Epub 2024 Jun 21.
7
SARS-CoV-2 co-detection with influenza and human respiratory syncytial virus in Ethiopia: Findings from the severe acute respiratory illness (SARI) and influenza-like illness (ILI) sentinel surveillance, January 01, 2021, to June 30, 2022.2021年1月1日至2022年6月30日埃塞俄比亚严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）与流感及人呼吸道合胞病毒的联合检测：来自严重急性呼吸道疾病（SARI）和流感样疾病（ILI）哨点监测的结果
PLOS Glob Public Health. 2024 Apr 18;4(4):e0003093. doi: 10.1371/journal.pgph.0003093. eCollection 2024.
8
Antibacterial agents used in COVID-19: A systematic review and meta-analysis.用于新型冠状病毒肺炎的抗菌药物：一项系统评价与荟萃分析
Environ Sustain (Singap). 2021;4(3):503-513. doi: 10.1007/s42398-021-00194-6. Epub 2021 Jun 7.
9
Clinical and immunologic features of co-infection in COVID-19 patients, along with potential traditional Chinese medicine treatments.新型冠状病毒肺炎合并感染的临床和免疫学特征及潜在的中医药治疗。
Front Immunol. 2024 Mar 21;15:1357638. doi: 10.3389/fimmu.2024.1357638. eCollection 2024.
10
Total Infectome Characterization of Respiratory Infections during the 2022-23 COVID-19 Outbreak in China Revealed Extensive Coinfections with Links to SARS-CoV-2 Status, Age, and Disease Severity.2022-2023年中国新冠疫情期间呼吸道感染的全感染组特征揭示了与新冠病毒状态、年龄和疾病严重程度相关的广泛合并感染。
Pathogens. 2024 Feb 29;13(3):216. doi: 10.3390/pathogens13030216.

社区获得性共感染在 2019 年冠状病毒病中的作用：一项回顾性观察研究。

Community-acquired Coinfection in Coronavirus Disease 2019: A Retrospective Observational Experience.

机构信息

Section of Infectious Disease and Global Health, Department of Medicine, University of Chicago Medicine, Chicago, Illinois, USA.

Department of Pharmacy, University of Chicago Medicine, Chicago, Illinois, USA.

出版信息

Clin Infect Dis. 2021 Apr 26;72(8):1450-1452. doi: 10.1093/cid/ciaa902.

DOI:10.1093/cid/ciaa902
PMID:32604413
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7337635/
Abstract

Community-acquired coinfection in coronavirus disease 2019 (COVID-19) is not well defined. Current literature describes coinfection in 0-40% of COVID-19 patients. In this retrospective report, coinfection was identified in 3.7% of patients and 41% of patients admitted to intensive care (P < .005). Despite infrequent coinfection, antibiotics were used in 69% of patients.

摘要

社区获得性合并感染在 2019 年冠状病毒病（COVID-19）中尚未明确界定。目前的文献描述 COVID-19 患者中有 0-40%合并感染。在本回顾性报告中，3.7%的患者和 41%的重症监护病房（ICU）患者被确定为合并感染（P<.005）。尽管合并感染并不常见，但抗生素仍在 69%的患者中使用。